Author: Chrisanne Sternal

British scientists are conducting the first study on the human genome to determine the genetic causes of osteoarthritis.

Timothy Spaulding, a Top Health Blogger  for the Arthritis Community on Well sphere  and author of the  Current Arthritis News and Research Blog  explains in his recent   article   about The Genetic Link to Osteoarthritis.

The two year study will help researchers find and develop drugs to block the genetic mutations that lead to the disease. 30 scientists at eight centers in the UK are currently seeking out 14,000 volunteers for the study, 6,000 healthy people and 8,000 who are awaiting, or have had, joint replacement surgery due to osteoarthritis.

There are half a million distinct regions in human DNA and it is expected that there are at least 100 genes that have a link to increased risk of OA. In fact, osteoarthritis is nearly three times more inheritable than breast cancer.

It is hoped that an outcome of the study, known as arcOGEN, is that within a few years an inexpensive test will be developed to identify people that are most likely to develop OA. Results of the study will be freely shared with other scientists around the world. The project has received is £2.2 million ($4.5 million) from the Arthritis Research Campaign (ARC).

In many cases,  Flexcin can help alleviate the pain associated with osteoarthritis. The primary component of Flexcin™ is CM8™ (cetyl myristoleate). Of all the ingredients in Flexcin, CM8™ is the most powerful. CM8™ functions in three different ways. First, it acts as a highly effective lubricant in the joints, muscles and other tissues, allowing them to move smoothly. Decrease or loss of morning stiffness is commonly noted shortly after commencing treatment. Next, CM8™ functions as an anti-inflammatory. Relief from swollen joints is often seen after the 4th or 5th week of treatment. Third, it is also an immune system modulator, which can be effectual against autoimmune diseases, such as arthritic conditions. CM8™ relieves joint pain at its source, reducing inflammation and irritation of the joints and tissues.

Read more of Timothy Spaulding’s interesting topics on his Current Arthritis News and Research Blog.

FINE PRINT
This policy is valid from 12 November 2009. I am C. Small, the administrator for this blog. For questions about this blog, please contact cvsmall.small@gmail.com. This blog does not accept any form of cash advertising, sponsorship, or paid topic insertions. However, since I am an Affiliate of the advertisers in this blog, if you buy something I will get paid, not much but I’m retired and need whatever I can get. The compensation received may influence the advertising content, topics or post made in this blog. That content, advertising space or post may not always be identified as paid or sponsored content. Even though I receive compensation for the advertisements, I always give my honest opinions, findings, beliefs, or experiences on those products. The views and opinions expressed on this blog may not be my own, but I agree with them. Any product claim, statistic, quote or other representation about a product or service should be verified with the manufacturer, provider or party in question. This blog does contain content which might present a conflict of interest. This content may not always be identified.

Tags: arthritis, flexcin, genetics, osteoarthritis, research

This entry was posted on Tuesday, January 5th, 2010 at 12:44 pm and is filed under health conditions. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.